The New York Times
1 个月前
Aduhelm, a controversial new drug for treating Alzheimer’s disease, should be given to a much narrower group of patients than the FDA's approval permits, said Alzheimer's experts – including those who supported approval of the drug. https://t.co/mNkMsxWRFD

没有翻译

请帮助翻译为中文(简体)吧。

评论 0
中文(简体) 中文(繁體) English 한국어 日本語 العربية Polski Deutsch Русский français suomi Tagalog Nederlands Čeština Bahasa Melayu Português Svenska ไทย Türkçe Español Italiano हिन्दी, हिंदी Indonesia Tiếng Việt Kiswahili Burmese English(British) français(canadien) ខ្មែរ, ខេមរភាសា, ភាសាខ្មែរ Português(Brasil) Español(Latinoamérica)